Read by QxMD icon Read

Breast cancer AND estrogen

Chandan Kanta Das, Aditya Parekh, Pratap Kumar Parida, Sujit Kumar Bhutia, Mahitosh Mandal
Estrogen receptor (ER) antagonist, tamoxifen has been universally used for the treatment of the ER-positive breast cancer; however, inevitable emergence of resistance to tamoxifen obstructs the successful treatment of this cancer. So, there is an immediate requirement for the search of a novel therapeutic target for treatment of this cancer. Acquired tamoxifen resistant breast cancer cell lines MCF-7 (MCF-7/TAM-R) and T47D (T47D/TAM-R) showed higher apoptotic resistance accompanied by induction of pro-survival autophagy compared to their parental cells...
March 13, 2019: Biochimica et biophysica acta. Molecular cell research
Jeffrey Landercasper, Luis D Ramirez, Andrew J Borgert, Humera F Ahmad, Benjamin M Parsons, Leah L Dietrich, Jared H Linebarger
BACKGROUND: Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectomy versus mastectomy in the National Cancer Database (NCDB). PATIENTS AND METHODS: A retrospective cohort of patients with stage I-III breast cancer in the NCDB (2004-2013) was identified...
February 21, 2019: Clinical Breast Cancer
Jeremy Johnson, Piotr Rychahou, Vitaliy M Sviripa, Heidi L Weiss, Chunming Liu, David S Watt, B Mark Evers
PURPOSE: Triple negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel AMPK activator that inhibits growth and induces apoptosis in colon cancer. The purpose of this project was to test the effects of FND-4b on AMPK activation, proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC...
2019: PloS One
In-Sung Song, Yu Jeong Jeong, Seung Hun Jeong, Ji Eun Kim, Jin Han, Tae-Hyun Kim, Sung-Wuk Jang
BACKGROUND/AIMS: Breast cancer is a clinically and molecularly heterogeneous disease. Patients with triple-negative breast cancer (TNBC) have poorer outcomes than those with other breast cancer subtypes due to lack of effective molecular targets for therapy. The present study aimed to the identification of estrogen receptor (ER)β as a novel mitochondrial target in TNBC cells, together with underlying mechanisms. METHODS: Expression of ERβ in clinical breast samples were examined by qRT-PCR, immunohistochemistry and immunoblotting...
2019: Cellular Physiology and Biochemistry
Pia Giovannelli, Marzia Di Donato, Ferdinando Auricchio, Gabriella Castoria, Antimo Migliaccio
Breast cancer (BC) is still characterized by high morbidity and mortality. A specific BC subtype named triple negative BC (TNBC) lacks estrogen and progesterone receptors (ER and PR, respectively) and is characterized by the absence of overexpression/amplification of human epidermal growth factor receptor 2 (HER2). The androgen receptor (AR) is expressed in TNBC, although its function in these cancers is still debated. Moreover, few therapeutic options are currently available for the treatment of TNBC. In this study, we have used TNBC-derived MDA-MB231 and MDA-MB453 cells that, albeit at different extent, both express AR...
March 14, 2019: Scientific Reports
Gianluca Franceschini, Alba Di Leone, Daniela Terribile, Martin Alessandro Sanchez, Riccardo Masetti
Aim of this paper is to allows to analyze a topic of great relevance and media interest such as the role of prophylactic mastectomy in healthy women with BRCA mutation proposing to the surgeons some useful informations for decision-making. Less than 15% of all breast cancers are associated with germline genetic mutations. The majority of hereditary breast tumors are due to mutations in BRCA1 and BRCA2 genes that are responsible for only one third of hereditary cases. The risk estimates are extremely heterogeneous with a mean cumulative lifetime breast cancer risk of approximately 72% in BRCA1 and 69% in BRCA2 by age 80...
2019: Annali Italiani di Chirurgia
Ishita Gupta, Rasha M Sareyeldin, Israa Al-Hashimi, Hamda A Al-Thawadi, Halema Al Farsi, Semir Vranic, Ala-Eddin Al Moustafa
Breast cancer is the most frequent cause of cancer-related deaths among women worldwide. It is classified into four major molecular subtypes. Triple-negative breast cancers (TNBCs), a subgroup of breast cancer, are defined by the absence of estrogen and progesterone receptors and the lack of HER-2 expression; this subgroup accounts for ~15% of all breast cancers and exhibits the most aggressive metastatic behavior. Currently, very limited targeted therapies exist for the treatment of patients with TNBCs. On the other hand, it is important to highlight that knowledge of the molecular biology of breast cancer has recently changed the decision-making process regarding the course of cancer therapies...
March 13, 2019: Cancers
Linjie Zhao, Shengtao Zhou, Jan-Åke Gustafsson
Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human physiology and pathology, serving as sensors of stimuli, master regulators of downstream molecular events and hubs governing complex gene regulatory networks. The importance of various members of the NR superfamily in cancer has led to substantial efforts to target them therapeutically. Notably, drugs that block the action of estrogen receptor alpha (ERα) in patients with ERα+ breast cancer or the androgen receptor (AR) in prostate cancer patients have provided remarkable improvements in survival...
March 14, 2019: Endocrine Reviews
Kayo Fukui, Norio Masumoto, Noriyuki Shiroma, Akiko Kanou, Shinsuke Sasada, Akiko Emi, Takayuki Kadoya, Michiya Yokozaki, Koji Arihiro, Morihito Okada
BACKGROUND: The presence of tumor-infiltrating lymphocytes (TILs) is a prognostic factor for breast cancer. However, because of tumor tissue heterogeneity, an accurate and simple evaluation method is needed. We determined if preoperative characteristic ultrasonography (US) image findings are predictive of lymphocyte-predominant breast cancer (LPBC). METHODS: We evaluated 191 patients with invasive breast cancer treated by curative surgery between January 2014 and December 2017...
March 13, 2019: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Ouchi, Kouichi Sakaguchi, Yoshifumi Fujita, Takayuki Matsuda, Makoto Kato, Eiichi Konishi, Tetsuya Taguchi
Aromatase inhibitors (AIs) are the gold standard therapy for breast cancer in postmenopausal women. AI suppresses the conversion of androgens to estrogens; however, this results in osteopenia, osteoporosis, and bone fracture, thus reducing the patient's quality of life. The use of adjuvant denosumab reduces the risk of clinical fractures in postmenopausal patients with breast cancer receiving AI. However, the efficacy of denosumab in the treatment of AI-associated bone loss has not been prospectively evaluated in Japan...
March 13, 2019: Journal of Bone and Mineral Metabolism
Zitong Zhao, Lin Li, Peina Du, Liying Ma, Weimin Zhang, Leilei Zheng, Bo Lan, Bailin Zhang, Fei Ma, Bo Xu, Qimin Zhan, Yongmei Song
Rationale: Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor alpha (ER-α), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR) expression, but the effect of lacking the three factors on TNBC is unclear. Whether loss of the three factors contributes to deregulate genes that participate in the progress of TNBC remains unknown. Methods: We performed microRNA arrays and comprehensive analysis to screen for miRNAs that are transcriptionally regulated by ER-α, HER2 and PR...
2019: Theranostics
Grecia I Uscanga-Perales, Sandra K Santuario-Facio, Celia N Sanchez-Dominguez, Servando Cardona-Huerta, Gerardo E Muñoz-Maldonado, Pablo Ruiz-Flores, Jose R Barcenas-Walls, Luis E Osuna-Rosales, Augusto Rojas-Martinez, Juan Francisco Gonzalez-Guerrero, Javier Valero-Gomez, Gabriela S Gomez-Macias, Alvaro Barbosa-Quintana, Oralia Barboza-Quintana, Raquel Garza-Guajardo, Rocio Ortiz-Lopez
Triple negative breast cancer (TNBC) is a subtype of breast cancer of heterogeneous nature that is negative for estrogen receptor (ER), progesterone receptor (PR) and growth factor human epidermal 2 (HER2) following immunohistochemical analysis. TNBC is frequently characterized by relapse and reduced survival. To date, there is no targeted therapy for this type of cancer. Chemotherapy, radiotherapy, and surgery remain as the standard treatments options. The lack of a target therapy and the heterogeneity of TNBC highlight the need to seek new therapeutic options...
March 2019: Oncology Letters
Siqing Cai, Miaomiao Yao, Donglu Cai, Jianxiang Yan, Meiling Huang, Lisheng Yan, Huirong Huang
In recent years, with increasing prevalence, particularly in young patients, breast cancer is considered to be one of the most common malignancies. The aim of the present study was to evaluate the clinical value of digital breast tomosynthesis (DBT) in diagnosing molecular subtypes of breast cancer. The present study retrospectively analyzed 134 cases of breast cancer with data regarding surgery, complete pathology and immunohistochemistry, which were collected at The Second Clinical College of Fujian Medical University (Quanzhou, China) between May 2013 and October 2014...
March 2019: Oncology Letters
Nicole M Kettner, Smruthi Vijayaraghavan, Merih Guray Durak, Tuyen Bui, Mehrnoosh Kohansal, Min Jin Ha, Bin Liu, Xiayu Rao, Jing Wang, Min Yi, Jason Pw Carey, Xian Chen, Thomas Kris Eckols, Akshara S Raghavendra, Nuhad K Ibrahim, Meghan Sri Karuturi, Stephanie S Watowich, Aysegul Sahin, David J Tweardy, Kelly K Hunt, Debu Tripathy, Khandan Keyomarsi
PURPOSE: CDK4/6 inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. While this treatment doubles time to progression compared to endocrine therapy alone, about 25-35% of patients do not respond, and almost all patients eventually acquire resistance. Discerning the mechanisms of resistance to CDK4/6 inhibition is crucial in devising alternative treatment strategies. EXPERIMENTAL DESIGN: Palbociclib resistant cells (MCF-7 and T47D) were generated in a step-wise dose-escalading fashion...
March 13, 2019: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Renée T Fortner, Julia Sisti, Boyang Chai, Laura C Collins, Bernard Rosner, Susan E Hankinson, Rulla M Tamimi, A Heather Eliassen
BACKGROUND: Epidemiologic data suggest that parity increases risk of hormone receptor-negative breast cancer and that breastfeeding attenuates this association. Prospective data, particularly on the joint effects of higher parity and breastfeeding, are limited. METHODS: We investigated parity, breastfeeding, and breast cancer risk by hormone-receptor (estrogen (ER) and progesterone receptor (PR)) and molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like) in the Nurses' Health Study (NHS; 1976-2012) and NHSII (1989-2013)...
March 12, 2019: Breast Cancer Research: BCR
Bernardo P de Almeida, Joana Dias Apolónio, Alexandra Binnie, Pedro Castelo-Branco
BACKGROUND: Breast cancer is a highly heterogeneous disease resulting in diverse clinical behaviours and therapeutic responses. DNA methylation is a major epigenetic alteration that is commonly perturbed in cancers. The aim of this study is to characterize the relationship between DNA methylation and aberrant gene expression in breast cancer. METHODS: We analysed DNA methylation and gene expression profiles from breast cancer tissue and matched normal tissue in The Cancer Genome Atlas (TCGA)...
March 12, 2019: BMC Cancer
Maria Francesca Santolla, Adele Vivacqua, Rosamaria Lappano, Damiano Cosimo Rigiracciolo, Francesca Cirillo, Giulia Raffaella Galli, Marianna Talia, Giuseppe Brunetti, Anna Maria Miglietta, Antonino Belfiore, Marcello Maggiolini
The FGF2/FGFR1 paracrine loop is involved in the cross-talk between breast cancer cells and components of the tumor stroma as cancer-associated fibroblasts (CAFs). By quantitative PCR (qPCR), western blot, immunofluorescence analysis, ELISA and ChIP assays, we demonstrated that 17β-estradiol (E2) and the G protein estrogen receptor (GPER) agonist G-1 induce the up-regulation and secretion of FGF2 via GPER together with the EGFR/ERK/c-fos/AP-1 signaling cascade in (ER)-negative primary CAFs. Evaluating the genetic alterations from METABRIC and TCGA datasets, we then assessed that FGFR1 is the most frequently amplified FGFRs family member and its amplification/expression associates with shorter survival rates in breast cancer patients...
March 7, 2019: Cells
Mingxin Tao, Tianci Song, Wei Du, Siyu Han, Chunman Zuo, Ying Li, Yan Wang, Zekun Yang
It is very significant to explore the intrinsic differences in breast cancer subtypes. These intrinsic differences are closely related to clinical diagnosis and designation of treatment plans. With the accumulation of biological and medicine datasets, there are many different omics data that can be viewed in different aspects. Combining these multiple omics data can improve the accuracy of prediction. Meanwhile; there are also many different databases available for us to download different types of omics data...
March 7, 2019: Genes
Michaela A Dinan, Lauren E Wilson, Shelby D Reed
BACKGROUND: This study examined whether associations between 21-gene recurrence score (RS) genomic testing and lower costs among patients with early-stage, estrogen receptor-positive breast cancer are observable in real-world data from the Medicare population. METHODS: A retrospective cohort study was conducted using SEER-Medicare data for a nationally representative sample of Medicare beneficiaries diagnosed from 2005 through 2011. The main outcomes were associations between RS testing and overall and chemotherapy-specific costs...
March 1, 2019: Journal of the National Comprehensive Cancer Network: JNCCN
Kamalpreet Kaur, Vikas Jaitak
BACKGROUND: Breast Cancer (BC) is the second most common cause of cancer related deaths in women. Due to severe side effects and multidrug resistance, current therapies like hormonal therapy, surgery, radiotherapy and chemotherapy become ineffective. Also, the existing drugs for BC treatment are associated with several drawbacks such as poor oral bioavailability, non-selectivity and poor pharmacodynamics properties. Therefore, there is an urgent need for the development of more effective and safer anti BC agents...
March 12, 2019: Anti-cancer Agents in Medicinal Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"